BioSpace News Archive

MiMedx Group, Inc., a transformational placental biologics company, announced the filing of its 2021 Annual Report on Form 10-K for the year ended December 31, 2021.

Jazz Pharmaceuticals plc announced that the Company will participate in the following upcoming virtual investor conferences.

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on April 5, 2022 to all shareholders of record as of March 15, 2022.

InVera Medical are delighted to announce the publication of its pre-clinical feasibility study of the InVera minimally invasive, exclusively mechanical venous ablation device in Phlebology, an official journal of several international venous societies.

Minerva Neurosciences, Inc. today announced that results from the Phase 3 clinical trial of roluperidone to treat negative symptoms in patients with schizophrenia have been published in Schizophrenia Bulletin.

ALR Technologies Inc., the diabetes management company, announced preliminary results from the Non-Inferiority Study currently being conducted on the GluCurve Pet CGM.

Gemini Therapeutics, Inc., a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration, provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.

Throne Biotechnologies, one of the global-leading biotech companies aiming to find a cure for type 1 diabetes, announced the launch of their Regulation Crowdfunding raise to support the United States FDA-approved phase 2 clinical trials of Stem Cell Educator therapy to treat type 1 diabetes, alopecia areata and other autoimmune diseases.

Alltrna announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs.